arrow
H

Hervé Ghesquières

Claude Bernard Lyon 1 University
H指数:57
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies

脾边缘区淋巴瘤987例患者的临床特征、治疗及长期预后分析以指导治疗和监测策略

2026-11-090
OA
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era

REALYSA队列研究中预CAR T时代一线治疗后难治性和早期复发性大B细胞淋巴瘤患者的结局

2026-09-060
OAAI
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

Englumafusp alfa联合glofitamab治疗b 细胞非霍奇金淋巴瘤: 1期试验

2026-07-160
OAAI
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy

滤泡性淋巴瘤患者一线免疫化疗后的无事件生存期全基因组关联研究

2026-01-090
OAAI
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

2025-12-100
OAAI
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

早期正电子发射断层扫描反应适应性治疗在低风险弥漫性大B细胞淋巴瘤中的应用:一项开放标签、多中心、随机、非劣效性III期临床试验。

2025-11-170
PRE
Risk stratification of diffuse large B-cell lymphoma patients using plasma NMR-based metabolomics at diagnostic

使用血浆NMR基代谢组学对弥漫性大B细胞淋巴瘤患者进行风险分层以用于诊断

2025-10-100
OAAI
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

一项关于LOXO-338(一种口服选择性Bcl-2抑制剂)在晚期血液系统恶性肿瘤患者中的首次人体I期研究

2025-01-280
PRE
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

异基因干细胞移植治疗复发/难治性ALK阳性间变性大细胞淋巴瘤:一项来自Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)的研究

BLOOD
IF23.1
2024-11-050
PRE
Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

老年患者经典霍奇金淋巴瘤的特异性分子异常经全基因组综合分析鉴定

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

利索卡巴肽马瑞克塞尔(liso-cel)在复发或难治性(R/R)滤泡性淋巴瘤(FL)患者(pts)中的2年随访:超越FL研究

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

根据既往Brentuximab Vedotin(BV)暴露情况,接受ASCT后应用BV作为维持治疗的霍奇金淋巴瘤患者的结局。EBMT淋巴瘤工作组与Geltamo、FIL、Lysarc和土耳其淋巴瘤组的回顾性分析。

BLOOD
IF23.1
2024-11-050
PRE